PARIS, June 17, 2024 /PRNewswire/ -- MGI (MGI Tech Co.,
Ltd. or its subsidiaries, together referred to MGI), a company
committed to building core tools and technologies that drive
innovation in life science, today announced the collaboration with
SeqOne, a leading provider of AI-driven genomic decision support
software, to develop and validate end-to-end genomic analysis
solutions from sample to report tailored to the needs of Human
Genetics and Pathology labs worldwide.
This collaboration between MGI and SeqOne encompasses three
distinct initiatives:
Validating an end-to-end, automated, cost-effective solution
for HRD signature with MGI DNBSEQ-G99
The collaboration between a Pathology Reference Lab in
Spain, Agilent Technologies, MGI,
and SeqOne aims to technically validate a routine workflow
leveraging Agilent panels, Magnis lib prep automation, MGI
DNBSEQ-G99, and SeqOne somaHRD, a clinically validated HRD
signature solution, on 96 samples.
This end-to-end solution for pathology molecular labs will
enable high-quality, efficient, and flexible HRD testing worldwide,
including Genomic Instability score and BRCA testing.
Enabling and validating SeqOne tertiary analysis solution
compatible with MGI Megabolt for Germline Panels, Whole Exome and
Whole Genome
MegaBOLT bioinformatics analysis accelerator, self-developed and
MPS-concentrated hardware accelerating system by MGI, is set to
ensure seamless integration and compatibility with SeqOne's
AI-powered variants identification and analysis solution.
The collaboration aims to combine MegaBOLT and the SeqOne
Platform to deliver a versatile, cost-effective, intuitive, and
time-saving solution from sample to report, particularly attractive
for high-throughput Human Genetics labs.
Validating SeqOne CE-IVD Platform for Germline and Somatic
analysis for use with MGI sequencers in routine diagnostics
This technical validation project aims to evaluate the
compatibility of the SeqOne Platform with MGI sequencing data. It
will validate variant calling performances on a set of reference
control samples in terms of QC, sensitivity and precision.
"We are thrilled to announce our collaboration with SeqOne. By
combining MGI's cutting-edge sequencing technology with SeqOne's
innovative genomic analysis Platform, we are poised to deliver real
insights and solutions for personalized healthcare," said Dr.
Yong Hou, General Manager of MGI
Europe and Africa. "This
collaboration underscores our commitment to advancing genomic
research and providing clinicians with the tools they need to offer
tailored treatments to their patients."
"This partnership with MGI strongly supports SeqOne's mission to
broaden access to sophisticated genomic analysis, aiming to improve
healthcare outcomes," said Martin
Dubuc, CEO, SeqOne. "Molecular laboratories globally are
exploring how MGI's sequencing and bioinformatics technologies can
advance next-generation sequencing (NGS) research and diagnostics.
We are eager to integrate SeqOne's CE-IVD Platform with MGI's
offerings, enhancing the quality, sensitivity, and precision of
bioinformatic analyses."
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to
MGI) is committed to building core tools and technologies that
drive innovation in life science. Our focus lies in research &
development, manufacturing, and sales of instruments, reagents, and
related products in the field of life science and biotechnology. We
provide real-time, multi-omics, and full spectrum of digital
equipment and systems for precision medicine, agriculture,
healthcare and various other industries. Founded in 2016, MGI has
grown into a leader in life science, serving customers across six
continents and have established research, manufacturing, training,
and after-sales service facilities globally. MGI stands out as one
of the few companies capable of independently developing and
mass-producing clinical-grade gene sequencers with varying
throughput capacities, ranging from Gb to Tb levels. With
unparalleled expertise, cutting-edge products, and a commitment to
global impact, MGI continues to shape the trajectory of life
sciences into the future. To learn more, please
visit https://en.mgi-tech.com/, LinkedIn, X,
and YouTube.
About SeqOne
SeqOne is a fast-growing deep-tech company focused on turning
genomic data into medically- actionable insights in oncology and
rare and inherited diseases. Our vision is to make personalized
healthcare a reality for every patient, everywhere. We are
committed to democratizing access to advanced genomic insights,
enabling labs of any size, in any location, to offer affordable
personalized medicine solutions to patients at scale. We integrate
cutting-edge AI and big data technologies to redefine genetic data
analysis. Our CE-IVD Platform provides time saving, flexible, and
cost-effective decision support, empowering decentralized
laboratories worldwide to deliver precision diagnostics.The company
has won numerous awards, including the iLab award and the ARC
Cancer Foundation's Hélène Stark prize. Investors include Elaia,
IRDI Capital Investissement, Merieux Equity Partners, Omnes, and
Software Club. To learn more, please visit www.seqone.com and
Linkedin.
Logo -
https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mgi-tech-and-seqone-partner-to-advance-end-to-end-genomic-analysis-302173987.html